Top acne content for Acne Awareness Month
Click Here to Manage Email Alerts
Acne is one of the most common skin disorders that affects a wide range of individuals but specifically targets those aged 12 to 24 years. In fact, 85% of people in this age range experience acne, according to Yale Medicine.
With June designated as Acne Awareness Month, Healio has compiled the most-read acne stories published so far in 2023 in an effort to continue raising awareness for this widespread condition:
Triple-combination acne gel set for FDA review
Bausch Health announced in May that the FDA has accepted their new drug application for investigational IDP-126 for the treatment of acne vulgaris. The drug is a combination of an antibiotic, an antibacterial and a retinoid: 1.2% clindamycin, 3.1% benzoyl peroxide and 0.15% adapalene, respectively. According to the announcement, the gel has potential to be a first-of-its-kind fixed-dose, triple-combination treatment in this indication. The FDA prescription drug user fee act date is set for Oct. 20. Read more.
Long-term safety, efficacy of clascoterone cream shown in acne treatment
At this year’s South Beach Symposium, researchers presented a poster showing that clascoterone cream 1% maintains long-term efficacy and a favorable safety profile in patients aged older than 12 years with acne vulgaris. The results are from a multicenter, open-label, long-term extension study from one of the 12-week phase 3 clinical trials of the drug. Up to 61.2% of clascoterone-treated patients achieved an IGA of 0/1 at the end of the trial. Read more.
‘Emerging need’ for alternative approaches to long-term antibiotic use in acne vulgaris
A recent study found that antibiotic use for the treatment of acne has frequently extended beyond the duration of 3 to 4 months recommended by the American Academy of Dermatology. This poses a problem because antibiotic resistance is associated with prolonged use. The authors of this study found that a majority of treatment courses lasted for approximately 9 months, greatly exceeding guidelines. This makes it clear that alternative options to prolonged antibiotic use are needed. Read more.
IBD risk in acne may be due to ‘shared mechanistic pathways’
A widely read study found that while acne was associated with incidence of inflammatory bowel disease, two drug classes used to treat acne had no such association. The drug classes in question were isotretinoin and oral tetracycline-class antibiotics. John S. Barbieri, MD, MBA, of the department of dermatology at Brigham and Women’s Hospital in Boston, told Healio that this finding was surprising as many other studies have suggested such an association. Nevertheless, acne continues to be associated with IBD. Read more.
IDP-126 may be first triple combination treatment for acne in children, adolescents
Lastly, the fixed-combination IDP-126 showed promising results as the first triple-combination product for the treatment of acne in patients aged as young as 9 years, according to a study. IDP-126, a novel clindamycin phosphate, is comprised of 1.2% benzoyl peroxide, 3.1% adapalene and 0.15% polymeric mesh gel. The gel exhibited a 55.8% success rate which was significantly greater than the vehicle gel success rate of 5.7%. There were no serious side effects with the most common issue being mild to moderate site irritation. Read more.